Panel Discussion: Strengthening Cross-Disciplinary Collaboration to Improve ADC Toxicity Prediction & Management
Time: 1:15 pm
day: Scientific Program Day One
Details:
The lack of structured communication between translational teams, oncologists, and ophthalmologists creates a major barrier in ADC toxicity prediction and management. This panel will explore how to establish a collaborative care model that improves early detection, toxicity grading, and back-translation for ADC toxicities like ILD and ocular inflammation.
Discussion points include:
- How can we better educate clinical trial investigators to recognize and escalate ILD/ocular toxicities and what early intervention or prevention strategies can prevent discontinuations?
- How can we treat patients once the toxicities have been established? Can patients be re-challenged with ADC drugs following previous ADC associated toxicities?
- What can clinical specialists teach preclinical teams about improving ADC toxicity models and at what point of ADC treatment should each specialist be involved to achieve proactive toxicity mitigation?
- How can we design models that better reflect real-world toxicities in ocular, pulmonary, and systemic tissues and what are the safety/toxicity profiles that would be deemed acceptable success ADC drugs through to the clinic
